Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 6/20 | 0.48 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857600 | 0.86 | TNIK (0.48) | PIK3CATNIKBTKITKNTRK1 | |
| SCHEMBL10263401 | 0.84 | AAK1 (0.49) | PIK3CABTKITKNTRK1PAK1 | |
| SCHEMBL857911 | 0.84 | KIT (0.52) | PIK3CATNIKNTRK1KITPAK1 | |
| SCHEMBL858062 | 0.83 | AXL (0.56) | ITKNTRK1PAK1DYRK1AAXL | |
| SCHEMBL858780 | 0.81 | BRD4 (0.51) | PIK3CANTRK1KITPAK1DYRK1A | |
| SCHEMBL878650 | 0.81 | TNIK (0.54) | PIK3CATNIKBTKITKNTRK1 | |
| SCHEMBL856931 | 0.80 | BTK (0.50) | PIK3CATNIKBTKITKKIT | |
| SCHEMBL857599 | 0.80 | BRAF (0.54) | PIK3CATNIKBTKITKPAK1 | |
| SCHEMBL297360 | 0.80 | CYP2C9 (0.56) | PIK3CATNIKBTKITKCYP2C9 | |
| SCHEMBL414867 | 0.80 | TNIK (0.53) | PIK3CATNIKBTKITKPAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | PIK3CA 27/4885TNIK 453/4885BTK 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.